cancer, with the goal of reporting results in 2009.
Peer-Reviewed Publications and Medical Meeting Presentations
-- Two abstracts were accepted for oral presentation at the San Antonio
Breast Cancer Symposium in December 2008:
-- "Risk of distant recurrence using Oncotype DX in postmenopausal
primary breast cancer patients treated with anastrozole or
tamoxifen: a TransATAC study"
-- "GRB7-dependent pathways are potential therapeutic targets in
triple-negative breast cancer"
-- The American Journal of Surgery published results of a study showing
Oncotype DX changed treatment recommendations in 44 percent of node-
negative, estrogen receptor-positive breast cancer patients.
-- Presented results from two studies supporting the use of Oncotype DX in
assessing HER2 gene expression at the ASCO Breast Cancer Symposium in
-- Independent researchers presented results from a small study of
Japanese women demonstrating that the Oncotype DX Recurrence Score(R)
result may predict response to neoadjuvant endocrine therapy including
tamoxifen and anastrozole at the ASCO Breast Cancer Symposium in
Conference Call Details
To access the live conference call today, November 5, at 4:30 p.m. Eastern Time via phone, please dial (877) 356-8064 from the United States and Canada or (706) 758-4314 internationally. The conference ID is 71000165. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12 and may be accessed by dialing (800) 642-1687 from the United States and Canada or (706) 645-9291 internationally. The replay passcode is 71000165.
To access the live and subsequently archived webcast of the conference
call, go to the Invest
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved